These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 17956710)

  • 21. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
    Dornbusch J; Zacharis A; Meinhardt M; Erdmann K; Wolff I; Froehner M; Wirth MP; Zastrow S; Fuessel S
    PLoS One; 2013; 8(9):e76386. PubMed ID: 24086736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells.
    Malec V; Coulson JM; Urbé S; Clague MJ
    J Proteome Res; 2015 Dec; 14(12):5263-72. PubMed ID: 26506913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
    Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.
    Figlin RA; Alvin H; Meinhardt CL
    Urologe A; 2004 Sep; 43 Suppl 3():S144-5. PubMed ID: 15179554
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
    J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
    Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
    Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
    Gerullis H; Ecke TH; Eimer C; Heuck CJ; Otto T
    Minerva Urol Nefrol; 2010 Dec; 62(4):411-23. PubMed ID: 20944541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.
    Gemmill RM; Zhou M; Costa L; Korch C; Bukowski RM; Drabkin HA
    Br J Cancer; 2005 Jun; 92(12):2266-77. PubMed ID: 15956968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
    Javle MM; Shroff RT; Xiong H; Varadhachary GA; Fogelman D; Reddy SA; Davis D; Zhang Y; Wolff RA; Abbruzzese JL
    BMC Cancer; 2010 Jul; 10():368. PubMed ID: 20630061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VHL Expression in Kidney Cancer: Relation to Metastasis Development, Transcription and Growth Factors and Component of Akt/m-TOR Signaling Pathway.
    Spirina LV; Kondakova IV; Yurmazov ZA; Usynin EA; Slonimskaya EM; Lushnikova NA; Podnebesnova DV
    Bull Exp Biol Med; 2019 Sep; 167(5):671-675. PubMed ID: 31625068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma].
    Salinas-Sánchez AS; Giménez-Bachs JM; Serrano-Oviedo L; Nam Cha S; Sánchez-Prieto R
    Actas Urol Esp; 2012 Feb; 36(2):99-103. PubMed ID: 21959062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).
    Tinker AV; Ellard S; Welch S; Moens F; Allo G; Tsao MS; Squire J; Tu D; Eisenhauer EA; MacKay H
    Gynecol Oncol; 2013 Aug; 130(2):269-74. PubMed ID: 23672928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.
    Duran I; Kortmansky J; Singh D; Hirte H; Kocha W; Goss G; Le L; Oza A; Nicklee T; Ho J; Birle D; Pond GR; Arboine D; Dancey J; Aviel-Ronen S; Tsao MS; Hedley D; Siu LL
    Br J Cancer; 2006 Nov; 95(9):1148-54. PubMed ID: 17031397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.
    Patard JJ; Fergelot P; Karakiewicz PI; Klatte T; Trinh QD; Rioux-Leclercq N; Said JW; Belldegrun AS; Pantuck AJ
    Int J Cancer; 2008 Jul; 123(2):395-400. PubMed ID: 18464292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
    Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
    Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
    Meyer LA; Slomovitz BM; Djordjevic B; Westin SN; Iglesias DA; Munsell MF; Jiang Y; Schmandt R; Broaddus RR; Coleman RL; Galbincea JM; Lu KH
    Int J Gynecol Cancer; 2014 May; 24(4):713-7. PubMed ID: 24651628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway.
    Italiano A; Kind M; Stoeckle E; Jones N; Coindre JM; Bui B
    Anticancer Drugs; 2011 Jun; 22(5):463-7. PubMed ID: 21301319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations.
    Pinato DJ; Ramachandran R; Toussi ST; Vergine M; Ngo N; Sharma R; Lloyd T; Meeran K; Palazzo F; Martin N; Khoo B; Dina R; Tan TM
    Br J Cancer; 2013 Feb; 108(2):429-37. PubMed ID: 23257898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.